ACTRN12605000705684
Recruiting
Phase 3
A prospective randomised phase III trial evaluating the effect of more intensive information on patient satisfaction and anxiety.
Perth Radiation Oncology Centre0 sites212 target enrollmentNovember 2, 2005
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Anxiety levels
- Sponsor
- Perth Radiation Oncology Centre
- Enrollment
- 212
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patient must be having radical radiotherapy.The patient must have a good understanding of english.The patient must be able to complete questionnaire unaided.Used only for patients diagnosed with Breast,Lung,Prostate,Rectal and Gynaecological cancer.
Exclusion Criteria
- •A poor understanding of written english.Significant visual impairment and previous radiation therapy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 14.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-FRAGO Research GmbH796
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 19.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-DKAGO Research GmbH796
Active, not recruiting
Phase 1
Evaluation of optimal initial treatment duration of bevacizumab in combination with carboplatin and paclitaxel in patients with ovarian cancer.Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinomas with indication for a platin/paclitaxel chemotherapyMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-DEAGO Research GmbH900
Active, not recruiting
Phase 1
The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) TrialEpithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, FIGO Stages IIb-IVMedDRA version: 14.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-001015-32-FIJohanna Mäenpää796
Active, not recruiting
Phase 1
The aim of this trial, which is called FRAGMATIC, is to assess the effect of adding a blood thinning drug called dalteparin (FRAGMIN®) for 24 weeks to standard treatment for patients with lung cancer to see if if has any affect on survival.ung cancerMedDRA version: 14.1 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2005-002438-37-GBVelindre NHS Trust2,202